Every once in a while, investors come across some of the best names in a given industry, which then become subject to the best news and developments during a holding period. Today’s best pick seems to be in the medical sector. It shows investors a major fundamental strength that has been noticed by other major players in the industry, pushing future upside potential higher. Hims & Hers Health TodayHIMSHims & Hers Health$32.11 -2.93 (-8.35%) 52-Week Range$11.20▼$72.98P/E Ratio72.99Price Target$36.92Add to W ...

Company Overview - Hims & Hers Health, Inc. (HIMS) shares increased by 23% to close at $35.04, with trading volume significantly higher than usual, contrasting with a 3.6% loss over the previous four weeks [1][2] Recent Developments - The surge in Hims & Hers Health's shares is linked to the announcement of a deal to sell Novo Nordisk's weight-loss drug, Wegovy, on its telehealth platform, allowing U.S. customers to access NovoCare Pharmacy through Hims & Hers for $599 per month [2] Financial Performance Expectations - The company is projected to report quarterly earnings of $0.14 per share, reflecting a year-over-year increase of 180%, with revenues expected to reach $537.85 million, a 93.4% rise from the same quarter last year [3] - The consensus EPS estimate for the upcoming quarter has been revised 21.3% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] Industry Context - Hims & Hers Health is categorized within the Zacks Medical Info Systems industry, where Health Catalyst (HCAT) is another player, having closed 0.3% higher at $4.07 but showing a -10.4% return over the past month [4]

Core Viewpoint - The article discusses the potential for investing in undervalued stocks that are mispriced by the market, particularly focusing on the company HIMS and its stock performance. Group 1: Investment Opportunities - The article suggests that there may be beneficial long positions available in HIMS through stock purchases or call options within the next 72 hours [2]. - It emphasizes the importance of conducting personal research before making investment decisions, highlighting that past performance does not guarantee future results [4]. Group 2: Market Positioning - The article encourages investors to consider joining platforms like Out Fox The Street for insights on positioning in undervalued stocks [1]. - It notes that the opinions expressed are those of the author and may not reflect broader market views, indicating a level of independence in the analysis [4].

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Insights - Novo Nordisk and Hims & Hers Health announced a long-term collaboration to enhance access to Wegovy (semaglutide) through a direct-to-patient delivery service [1][3] - The Wegovy savings program has been updated to allow cash-paying patients to access injections at a reduced cost of $499 per month at local pharmacies [2] - Hims & Hers is expanding its weight loss solutions, with its GLP-1 offering generating over $225 million in revenue in 2024 [5] Group 1: Collaboration and Offerings - Novo Nordisk introduced NovoCare Pharmacy, allowing Americans to access Wegovy directly through the Hims & Hers platform, which includes a bundled offering of all dose strengths of Wegovy and a membership for ongoing support [1][3] - A unified price for Wegovy starts at $599 per month, available on the Hims & Hers platform, aiming to improve long-term health outcomes [3] Group 2: Financial Impact and Market Response - Hims & Hers stock increased by 35.5% to $38.60 during the premarket session following the announcement of the collaboration [5] - The collaboration aims to combine Novo Nordisk's treatments with Hims & Hers' ability to scale access to quality care, enhancing the overall market for weight loss solutions [3][4]

Core Insights - Hims & Hers Health has announced a collaboration with Novo Nordisk to bundle the weight-loss drug Wegovy with its telehealth membership, providing 24/7 care, clinical support, and nutrition guidance [1][5] - The partnership aims to enhance consumer-centered healthcare and is seen as a significant step towards achieving that vision, as stated by Hims & Hers CEO Andrew Dudum [2] - Following the announcement, shares of Hims & Hers surged by 25% [2] Pricing and Availability - The bundled service will have a starting price of $599 per month [4] - Wegovy will be available in all dosage strengths through Hims & Hers' platform, which will also include access to Novo Nordisk's NovoCare Pharmacy for cash-paying patients [4][5] Future Developments - Hims & Hers and Novo Nordisk are working on a roadmap to integrate innovative treatments with the telehealth platform's capabilities to scale access to quality care [7] - Other telehealth companies, such as Ro and Life MD, have also announced partnerships with Novo Nordisk to offer Wegovy and integrate NovoCare Pharmacy into their platforms [9] Market Context - Wegovy is part of a popular class of GLP-1 medications for weight loss, alongside Novo's Ozempic and Eli Lilly's Zepbound and Mounjaro [10]

I'm a retired Wall Street PM specializing in TMT; since kickstarting my career, I've spent over two decades in the market navigating the technology landscape, focusing on risk mitigation through the dot com bubble, credit default of '08, and, more recently, with the AI boom. In one word, what I'd like my service to revolve around is momentum. Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within t ...

Core Viewpoint - Hims & Hers Health's stock surged by up to 45% following the announcement of a partnership with Novo Nordisk to offer Wegovy through its platform, indicating strong investor interest in the company's growth potential in the weight-loss medication market [1][5]. Stock Performance - In pre-market trading, HIMS stock rose as much as 45% to $41, later stabilizing at a 26% increase to $36.17 at the time of reporting [2]. - The stock has experienced a 43% year-to-date increase, reflecting positive market sentiment [4]. Partnership Details - The partnership allows Hims & Hers to offer Wegovy prescriptions starting at $599 per month via NovoCare Pharmacy, expanding access to a high-demand weight-loss medication previously available only through local pharmacies [5]. - This collaboration is expected to unlock a significant new revenue stream for Hims & Hers, which has been growing its subscription-based health offerings [6]. Market Demand - The move positions Hims & Hers to capitalize on the increasing demand for weight-loss medications, particularly GLP-1 drugs [7]. Analyst Reactions - Despite the positive news, several Wall Street analysts downgraded HIMS stock, citing limited near-term upside and potential speculative trading [8][9]. - Morgan Stanley reduced its price target from $60 to $40 while maintaining an 'Equal Weight' rating, emphasizing the need for clear progress in Hims' core business [9]. - TD Cowen downgraded HIMS to 'Hold' from 'Buy', cutting its target to $30, and raised concerns about competition and the achievability of the company's $725 million weight-loss revenue target [10]. - Citi reaffirmed its 'Sell' rating and lowered its price target from $27 to $25, highlighting risks related to slowing core revenue growth and broader market pressures [11].

Core Insights - Novo Nordisk is expanding access to its weight loss drug Wegovy through telehealth providers Hims & Hers Health, Ro, and Life MD, as supply shortages have eased in the U.S. [1][2] - Hims & Hers shares surged 40% in premarket trading, while Novo Nordisk's stock rose 3% following the announcement [2]. Company Strategies - Novo Nordisk aims to capture more patients by collaborating with telehealth companies, as compounding pharmacies face legal restrictions on producing cheaper, unapproved versions of Wegovy [2][3]. - The partnerships with telehealth providers are designed to create a seamless experience for patients, allowing them to access Wegovy directly from their providers [4]. Pricing and Accessibility - Wegovy will be offered at $499 per month through Novo Nordisk's direct-to-consumer online pharmacy, which is about half of its usual list price for uninsured patients [5]. - Hims & Hers will provide Wegovy starting at $599 per month, which includes additional services such as 24/7 care and nutritional guidance [5][6]. Market Context - Hims & Hers has previously offered compounded versions of semaglutide but is now transitioning to the branded Wegovy due to regulatory changes [9]. - The FDA has set deadlines for compounding pharmacies to cease the production of unapproved versions of semaglutide, impacting the availability of alternatives [10].